key: cord-0950291-z9nhkhyn
authors: Sarwar, Raiya; Adeyi, Oyedele A.; Lake, John; Lim, Nicholas
title: Acute cellular rejection in liver transplant recipients following vaccination against COVID‐19: A case series
date: 2022-03-04
journal: Liver Transpl
DOI: 10.1002/lt.26446
sha: 47e5435ef8b80a3aa4037766b88ddeddafe299f4
doc_id: 950291
cord_uid: z9nhkhyn

‐

Most adverse events related to the COVID-19 vaccines are attributed to local side effects related to vaccine reactogenicity. However, there are reports of more serious reactions to COVID-19 vaccines possibly related to their immunogenicity, including one report describing several cases of new onset autoimmune hepatitis. (2) In LT recipients, there has been one case report to date of biopsy-proven ACR after receiving a COVID-19 vaccine, albeit in the context of tapering off corticosteroids in the early post-transplant period. (3) We report a case series of 5 LT recipients who developed biopsy-proven acute cellular rejection following vaccination against COVID-19.

Four out of five patients were male. The median age was 54 years. The indications for LT were non-alcoholic steatohepatitis-related cirrhosis in three patients and alcohol-related cirrhosis in two patients. The mean time from LT to the first dose of COVID-19 vaccination was 19 months (range 7-26 months). Two patients had a history of ACR at 40 days and 418 days post-LT (195 and 370 days prior to the first dose of COVID-19 vaccination respectively). All patients had negative COVID-19 PCR tests prior to their liver biopsies. (Table 1) .

Two patients were on calcineurin-inhibitor monotherapy while one patient was on calcineurin-inhibitor and antimetabolite therapy at the time of the first dose of COVID-19 vaccination. The remaining two patients

This article is protected by copyright. All rights reserved were taking mycophenolate mofetil 750 mg twice daily and prednisone 5 mg daily. Where appropriate, prevaccination immunosuppression trough levels were in the target range for all patients.

Three patients received the Moderna COVID-19 vaccination while two patients received the Pfizer-BioNtech COVID-19 vaccination. All patients completed their vaccination series. One patient had a delayed second dose of vaccination (110 days after first dose of Pfizer-BioNtech COVID-19 vaccination) due to treatment of ACR.

Three patients developed elevation in their liver enzymes after the first dose of the COVID-19 vaccination.

The median time from vaccination (3 patients after 1 st dose and 2 patients after 2 nd dose) to elevation in liver enzymes was 11 days (range 7-19 days).

All patients underwent liver biopsy following abnormal liver enzymes. Adequate samples were obtained from all five patients ( Figure 1A -E) which demonstrated typical features of T cell-mediated ACR including portal inflammation of predominantly mixed activated lymphocytes, portal vein phlebitis (black arrows) and bile duct injuries (red arrows). C4d stain by immunohistochemistry was negative in all but one patient, who showed C4d in the portal vein (PV), portal connective tissue and small portal capillaries ( Figure 2F ). Three patients had RAI 5 out of 9, whereas the other two had 3 out of 9. (Table 1) .

Two patients required hospital admission for treatment of ACR. All patients were initially treated with high dose intravenous methylprednisolone for 3 days. Three patients were started on an additional immunosuppressive medications. No patients required treatment with anti-thymocyte globulin.

This article is protected by copyright. All rights reserved Liver enzymes returned to normal (or baseline) in all patients following treatment for ACR. Three patients had normalization of liver enzymes within 2 weeks of intravenous methylprednisolone. One patient had normalization of liver enzymes after 75 days following treatment of ACR. No patients required readmission to hospital, died or developed graft failure. No patients had COVID-19 antibody titers checked during or after their vaccination series. And no patients developed symptomatic COVID-19 infection during the follow-up period after vaccination and treatment of ACR.

Vaccination is a vital tool as the world works towards ending the COVID-19 pandemic. While ACR is rare following vaccination, no SOT recipients were included in the initial COVID-19 vaccine trials.(1) Case reports of patients developing autoimmune hepatitis linked to COVID-19 vaccination have postulated that molecular mimicry to the spike protein S1 may stimulate upregulation of pro-inflammatory pathways, which could also theoretically induce ACR in susceptible patients. (4) Our cohort of patients did not all have typical risk factors associated with ACR: all patients were older than 50 years old while none underwent LT for autoimmune liver disease. One patient did have a history of late ACR at 14 months post-LT but was taking both a calcineurin-inhibitor and an antimetabolite at the time of vaccination. Two patients were maintained on less intense immunosuppression regimens but had been stable for several months prior to receiving their first dose of vaccine. Every patient in our cohort required treatment with intravenous corticosteroids and up-titration of their maintenance immunosuppression which eventually resulted in normalization of liver enzymes. In contrast, in

This article is protected by copyright. All rights reserved a recent report, a patient who may have developed ACR following COVID-19 vaccination required rescue therapy with ATG for severe, persistent ACR.(3) Of note, three patients in our cohort developed ACR after their first dose of the COVID-19 vaccine. However, each individual eventually received their second dose of the COVID-19 vaccine without complication. Our limited experience can provide some reassurance to providers concerned about the development of ACR in LT recipients receiving booster vaccine doses. COVID-19 antibodies were not checked in our cohort during or after vaccination so it is not clear how they may guide booster vaccinations or how treatment of ACR may affect serum levels. While prophylactic monoclonal antibodies conferring passive immunity against COVID-19 are currently available, active vaccination should still be considered the primary defense against COVID-19 in SOT recipients, given its proven track record. For now, we would simply recommend that liver enzymes are monitored in LT recipients soon after any COVID-19 vaccination to identify any potential development of ACR.

In summary, we report a series of LT recipients who developed ACR following their COVID-19 vaccinations.

Our findings highlight the need for comprehensive post-vaccination surveillance programs in patients where the high immunogenicity of vaccines could potentially provoke adverse events. It is important to note that all episodes of ACR in our series were easily treated without any serious complications and our preliminary findings should not be used to discourage vaccination for COVID-19 in LT recipients. Further study is clearly required to better understand this association in a patient population that is at higher risk of both acquiring, and developing serious complications, of COVID-19 infection. 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Liver injury following SARS-CoV-2 vaccination: A multicenter case series

Steroid-Resistant Acute Cellular Rejection of the Liver After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?

Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients

Acute rejection after anti